secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001558370-25-003304
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor Therapeutics reports Q4 net loss $7.1M, BLA for deramiocel accepted with PDUFA Aug 31, 2025
--------------------------------------------------------------------------------

- FDA accepted BLA for deramiocel to treat DMD cardiomyopathy; Priority Review, PDUFA date August 31, 2025.
- HOPE-2 OLE data showed 52% slowing of disease progression over 3 years vs external comparator (p=0.019).
- Cash balance $151.5M at Dec 31, 2024; received $10M milestone from Nippon Shinyaku in Jan 2025; cash runway into 2027.
- Q4 2024 revenue $11.1M (vs $12.1M Q4 2023); net loss $7.1M ($0.16/share) vs $0.8M loss ($0.02/share).
- Full year 2024 net loss $40.5M ($1.15/share) vs $22.3M ($0.83/share) in 2023; operating expenses $64.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837025003304/0001558370-25-003304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837025003304/capr-20250319x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-003304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer